FDA Approves New Pancreatic Cancer Therapy Rasonque
Revolution Medicines' daraxonrasib targets KRAS mutations, offering new hope for advanced cases months ahead of schedule.
Sarah Connor
The Food and Drug Administration today approved daraxonrasib, a new therapy for advanced pancreatic cancer.
Rasonque, a drug focused on KRAS mutations, targets a common driver in many cancers.
Kyle Diamantas affirmed, "It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible."
It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible.
The American Cancer Society estimates approximately 67,000 new cases of pancreatic cancer will be diagnosed in the United States this year, with over 52,000 deaths.
The FDA claims the drug is approved for pancreatic cancer patients with metastatic disease who have already undergone chemotherapy.
Patients receiving the new treatment reportedly lived a median of 13.2 months, compared to 6.7 months for those on chemotherapy.
Revolution Medicines claims patients taking the drug nearly doubled their survival time, experiencing fewer severe side effects.
Ben Sasse offered a personal account of the drug's impact, claiming daraxonrasib has helped shrink his tumors.
Doctors have warned of an increasing number of patients in their 20s, 30s, and 40s being diagnosed over the past two decades, often without classic risk factors.
Side effects of daraxonrasib include skin rash, mouth sores, diarrhea, and other digestive issues.
Revolution Medicines has not yet announced the medication's cost, the company claims.